FMP
IO Biotech, Inc.
IOBT
NASDAQ
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
1.45 USD
-0.01 (-0.69%)
About
ceo
Dr. Mai-Britt Zocca Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.iobiotech.com
exchange
NASDAQ
Description
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was i...
CIK
0001865494
ISIN
US4497781090
CUSIP
449778109
Address
Ole Maaløes Vej 3
Phone
45 70 70 29 80
Country
DK
Employee
68
IPO Date
Nov 5, 2021
Summary
CIK
0001865494
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
449778109
ISIN
US4497781090
Country
DK
Price
1.45
Beta
0.5
Volume Avg.
137.69k
Market Cap
95.53M
Shares
-
52-Week
0.816-2.64
DCF
3.23
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.73
P/B
-
Website
https://www.iobiotech.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest IOBT News
It looks like there's no news available.
